Press release
Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit
- TIGIT and PVRIG are key parallel and complementary inhibitory pathways in the DNAM-1 axis which intersect with the well-established PD-1 pathway - First
About this update from Compugen Ltd.
[{"type":"text","content":"- TIGIT and PVRIG are key parallel and complementary inhibitory pathways in the DNAM-1 axis which intersect with the well-established PD-1 pathway\n - First demonstration of immune activation in the tumor microenvironment after PVRIG blockade with COM701 monotherapy and in combination with nivolumab based on patient biopsies\n - Builds upon prior data showing immune activation in patients peripheral blood including peripheral induction of activated dendritic cell markers in patients who responded to treatment with COM701 in combination with nivolumab\n - Data support the distinct role of PVRIG in the DNAM-1 axis which may be important for driving immune activation in indications unlikely to respond to PD-1 blockade\n\n\nHOLON, Israel, Dec. 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary translational data from patient biopsies demonstrating immune activation in the tumor microenvironment (TME) after treatment with COM701, Compugen's potentially first-in-class anti-PVRIG antibody, as a monotherapy and in combination with nivolumab at the TIGIT Therapies Digital Summit.\n\"These translational data are exciting as they represent the first demonstration of immune activation in the TME of patients who have been treated with COM701 monotherapy or in combination with nivolumab and add to previous data showing immune activation in peripheral blood taken from treated patients,\" said Eran Ophir, Ph.D., Vice President of Research and Drug Discovery at Compugen. \"In addition, we are encouraged by the observed increases in clonal expansion of T cells, immune infiltration and immune activation in an MSS-CRC patient with a confirmed response after COM701 and nivolumab combination therapy given this is an indication that is unlikely to respond to PD-(L)1 blockade. These results are consistent with our earlier findings supporting PVRIG pathway involvement in early differentiation memory T cell priming and activation and provide important evidence of immune modulation at the location critical for efficacy, the tumor site.\"\nDr. Ophir continued \"These data, combined with our earlier findings suggest PVRIG plays a distinct role within the DNAM-1 axis. We look forward to continued investigation of PVRIG...